Can a single drug boost blood counts and delay cancer in High-Risk patients?
NCT ID NCT06788691
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the drug luspatercept in 50 adults with clonal cytopenias of uncertain significance (CCUS), a condition where low blood cell counts increase the risk of developing blood cancers like leukemia. Participants receive injections every three weeks for up to 48 weeks. The goal is to see if the drug can safely raise red blood cells, platelets, or white blood cells and delay progression to more serious disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Weill Cornell Medical College
RECRUITINGNew York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can less be more? testing transfusion limits in ECMO
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- A simple blood test trend may flag ICU patients at risk
- Rethinking anemia: does blood hemoglobin tell the whole story?
- Could a platelet-boosting drug shorten recovery after stem cell transplants?
- A simple nutrient may shield Babies' brains from iron deficiency